Publicacións en colaboración con investigadores/as de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (67)

2024

  1. Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human

    Vascular Pharmacology, Vol. 155

  2. Editorial: Therapeutics in pulmonary arterial hypertension

    Frontiers in Cardiovascular Medicine

  3. Role of KCNK3 Dysfunction in Dasatinib-associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction

    American journal of respiratory cell and molecular biology, Vol. 71, Núm. 1, pp. 95-109

  4. Vitamin D and Pulmonary Arterial Hypertension

    Archivos de Bronconeumologia

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Dietary Supplementation with a Cocoa–Carob Blend Modulates Gut Microbiota and Prevents Intestinal Oxidative Stress and Barrier Dysfunction in Zucker Diabetic Rats

    Antioxidants, Vol. 12, Núm. 8

  3. Glycolysis in pulmonary arterial hypertension and metabolic reprogramming

    Glycolysis: Tissue-Specific Metabolic Regulation in Physio-pathological Conditions (Elsevier), pp. 267-296

  4. Hydrogen sulfide regulates the redox state of soluble guanylate cyclase in CSE-/- mice corpus cavernosum microcirculation

    Pharmacological Research, Vol. 194

  5. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  6. Oxidized soluble guanylyl cyclase causes erectile dysfunction in alcoholic mice

    British Journal of Pharmacology, Vol. 180, Núm. 18, pp. 2361-2376

  7. Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart

    Journal of Physiology, Vol. 601, Núm. 17, pp. 3717-3737

  8. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

    PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063

  9. Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

    Pharmacological Research, Vol. 189

  10. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

    Frontiers in Pharmacology, Vol. 14

  11. Targeting IL-11 system as a treatment of pulmonary arterial hypertension

    Pharmacological research, Vol. 197, pp. 106985

  12. The novel KV7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit

    Biomedicine and Pharmacotherapy, Vol. 164

  13. Vitamin D Receptor Deficiency Upregulates Pulmonary Artery Kv7 Channel Activity

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

2022

  1. Antiproliferative miR-212-5p: Promising RNA therapy for pulmonary hypertension

    Molecular Therapy - Nucleic Acids

  2. Cardiac and Pulmonary Vascular Dysfunction in Vitamin D-Deficient Bmpr2-Mutant Rats

    American journal of respiratory cell and molecular biology

  3. Supplementation with a Cocoa–Carob Blend, Alone or in Combination with Metformin, Attenuates Diabetic Cardiomyopathy, Cardiac Oxidative Stress and Inflammation in Zucker Diabetic Rats

    Antioxidants, Vol. 11, Núm. 2